Article
News briefing: AstraZeneca follows Amgen down KRAS/SHP2 combo path; Vallon Pharmaceuticals files fo
Rating:
0.0
Views:
138
Likes:
1
Library:
1
Revolution Medicines is adding AstraZeneca to its roster of clinical collaborators, lending its lead drug, RMC-4630, for a study pairing it with the pharma giant's KRAS G12C program. AstraZeneca will sponsor and conduct the study once its now preclinical drug is ready for human studies, an arrangement similar to the
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value